Key result
90% of rheumatic patients lacking a SARS-CoV-2 mRNA vaccine response take multiple immunosuppressants.
Why the study?
Although most patients with rheumatic and musculoskeletal diseases develop robust responses to SARS-CoV-2 mRNA vaccination, a subset does not mount an appreciable humoral response.
What are the clinical characteristics of patients with rheumatic and musculoskeletal diseases who fail to mount a humoral response to 2-dose SARS-CoV-2 mRNA vaccination?
Population
20 patients with RMDs and undetectable anti-RBD antibodies after 2-dose SARS-CoV-2 mRNA vaccination
Design
Case series
Follow-up
Median of 30 days after the second dose
Authors
Loading...
May warrant serologic testing or additional doses in RMD patients on rituximab or mycophenolate; hypothesis-generating and requires confirmation in larger cohorts.
Case Report (n=20)
No
What are the clinical characteristics of patients with rheumatic and musculoskeletal diseases who fail to mount a humoral response to 2-dose SARS-CoV-2 mRNA vaccination?
Patients with rheumatic and musculoskeletal diseases receiving B-cell depleting therapies or mycophenolate may fail to mount a humoral response to SARS-CoV-2 mRNA vaccination.
Connolly et al. (2021) conducted a case report in Rheumatic and musculoskeletal diseases (n=20). SARS-CoV-2 messenger RNA vaccination was evaluated on Clinical characteristics of patients with absence of a humoral vaccine response. Among 20 patients with rheumatic and musculoskeletal diseases who failed to develop a humoral response 1 month after SARS-CoV-2 mRNA vaccination, 90% were receiving multiple immunosuppressive agents.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: